News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
240,509 Results
Type
Article (7501)
Company Profile (21)
Press Release (232986)
Multimedia
Podcasts (8)
Webinars (2)
Section
Business (63413)
Career Advice (307)
Deals (14816)
Drug Delivery (34)
Drug Development (36959)
Employer Resources (26)
FDA (6496)
Job Trends (4968)
News (122396)
Policy (11718)
Tag
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
Academia (576)
Accelerated approval (15)
Adcomms (8)
Allergies (68)
Alliances (14916)
ALS (68)
Alzheimer's disease (722)
Antibody-drug conjugate (ADC) (150)
Approvals (6762)
Artificial intelligence (200)
Autoimmune disease (78)
Automation (10)
Bankruptcy (147)
Best Places to Work (4640)
BIOSECURE Act (2)
Biosimilars (64)
Biotechnology (21)
Bladder cancer (115)
Brain cancer (35)
Breast cancer (279)
Cancer (2664)
Cardiovascular disease (172)
Career advice (273)
Career pathing (6)
CAR-T (180)
CDC (10)
Celiac Disease (1)
Cell therapy (412)
Cervical cancer (23)
Clinical research (33529)
Collaboration (642)
Compensation (205)
Complete response letters (20)
COVID-19 (804)
CRISPR (36)
C-suite (301)
Cystic fibrosis (72)
Data (3864)
Denatured (4)
Depression (59)
Diabetes (192)
Diagnostics (2373)
Digital health (12)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (87)
Drug pricing (61)
Drug shortages (19)
Duchenne muscular dystrophy (112)
Earnings (35576)
Editorial (20)
Employer branding (2)
Employer resources (21)
Events (33328)
Executive appointments (346)
FDA (8355)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (14)
Funding (571)
Gene editing (90)
Generative AI (18)
Gene therapy (265)
GLP-1 (280)
Government (1321)
Grass and pollen (2)
Guidances (288)
Healthcare (6166)
HIV (33)
Huntington's disease (15)
IgA nephropathy (59)
Immunology and inflammation (82)
Immuno-oncology (25)
Indications (64)
Infectious disease (925)
Inflammatory bowel disease (87)
Inflation Reduction Act (6)
Influenza (56)
Intellectual property (159)
Interviews (47)
IPO (8116)
IRA (20)
Job creations (578)
Job search strategy (224)
JPM (13)
Kidney cancer (12)
Labor market (17)
Layoffs (55)
Leadership (6)
Legal (2112)
Liver cancer (51)
Longevity (3)
Lung cancer (349)
Lymphoma (227)
Machine learning (17)
Management (7)
Manufacturing (290)
MASH (97)
Medical device (4774)
Medtech (4798)
Mergers & acquisitions (7355)
Metabolic disorders (501)
Multiple sclerosis (85)
NASH (8)
Neurodegenerative disease (115)
Neuropsychiatric disorders (33)
Neuroscience (1261)
NextGen: Class of 2026 (1510)
Non-profit (722)
Now hiring (16)
Obesity (206)
Opinion (106)
Ovarian cancer (112)
Pain (95)
Pancreatic cancer (147)
Parkinson's disease (123)
Partnered (11)
Patents (299)
Patient recruitment (296)
Peanut (19)
People (15214)
Pharmaceutical (8)
Pharmacy benefit managers (9)
Phase 1 (10771)
Phase 2 (14766)
Phase 3 (11037)
Pipeline (3245)
Policy (73)
Postmarket research (797)
Preclinical (3943)
Press Release (9)
Prostate cancer (128)
Psychedelics (13)
Radiopharmaceuticals (132)
Rare diseases (399)
Real estate (1025)
Recruiting (8)
Regulatory (10407)
Reports (16)
Research institute (536)
Resumes & cover letters (39)
Rett syndrome (22)
RNA editing (5)
RSV (30)
Schizophrenia (74)
Series A (86)
Series B (78)
Service/supplier (2)
Sickle cell disease (49)
Special edition (3)
Spinal muscular atrophy (34)
Sponsored (17)
Startups (685)
Stomach cancer (6)
Supply chain (40)
Tariffs (12)
The Weekly (3)
Vaccines (301)
Venture capital (18)
Weight loss (109)
Women's health (26)
Worklife (5)
Date
Today (4)
Last 7 days (286)
Last 30 days (1105)
Last 365 days (15100)
2026 (1392)
2025 (15128)
2024 (17010)
2023 (19154)
2022 (22299)
2021 (23709)
2020 (21869)
2019 (14478)
2018 (10671)
2017 (11484)
2016 (9566)
2015 (11758)
2014 (8115)
2013 (5889)
2012 (6047)
2011 (6771)
2010 (6267)
Location
Africa (183)
Alabama (28)
Alaska (2)
Arizona (77)
Arkansas (3)
Asia (18375)
Australia (5043)
California (5725)
Canada (1856)
China (553)
Colorado (223)
Connecticut (301)
Delaware (131)
Europe (29782)
Florida (869)
Georgia (119)
Hawaii (1)
Idaho (7)
Illinois (375)
India (53)
Indiana (203)
Japan (226)
Kansas (23)
Kentucky (10)
Louisiana (11)
Maine (44)
Maryland (637)
Massachusetts (3869)
Michigan (97)
Minnesota (194)
Missouri (63)
Montana (12)
Nebraska (8)
Nevada (79)
New Hampshire (46)
New Jersey (1816)
New Mexico (4)
New York (1671)
North Carolina (612)
North Dakota (2)
Northern California (2810)
Ohio (121)
Oklahoma (2)
Oregon (9)
Pennsylvania (1132)
Puerto Rico (11)
Rhode Island (12)
South America (305)
South Carolina (43)
Southern California (2293)
Tennessee (68)
Texas (882)
United States (19690)
Utah (132)
Virginia (137)
Washington D.C. (21)
Washington State (528)
West Virginia (2)
Wisconsin (25)
Wyoming (1)
240,509 Results for "csl limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
January 28, 2026
·
2 min read
Layoffs
CSL Overhauls Business With Vaccine Spinout, 15% Layoffs
With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.
August 20, 2025
·
1 min read
·
Tristan Manalac
Layoffs
Q3 Layoffs Up 280% YOY With CSL, Merck, Novo’s Restructurings
Due largely to CSL, Merck and Novo Nordisk’s reorganizations that could total about 19,350 people, Q3 cuts rose significantly year over year and quarter over quarter, based on
BioSpace
tallies.
October 16, 2025
·
4 min read
·
Angela Gabriel
Approvals
CSL Wins First Approval for Preventive Hereditary Angioedema Drug
Andembry is the first monthly Factor XIIa inhibitor for the prevention of HAE attacks and will be available to patients “before the end of June,” CSL announced.
June 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
October 27, 2025
·
3 min read
Press Releases
CSL announces rise in full year net profit
August 18, 2025
·
7 min read
Press Releases
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
September 26, 2025
·
6 min read
Press Releases
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
September 16, 2025
·
6 min read
Press Releases
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
October 7, 2025
·
7 min read
Press Releases
Health Canada Has Authorized CSL’s ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
August 11, 2025
·
6 min read
1 of 24,051
Next
